Novo Nordisk raises 2026 outlook again as Wegovy pills perform well
The company has raised its outlook three times this year. Wegovy pills are seen as a path to renewed growth, amid fierce competition with Lilly.
Related stories
eMudhra Reports September-Quarter Consolidated Net Profit of 327.6 Million Rupees
L impact | EARNINGS | Nov 04, 2026, 02:03 PM UTC
MGE Energy reports third-quarter EPS of $1.48
L impact | EARNINGS | Nov 04, 2026, 02:00 PM UTC
MGE Energy Reports Third-Quarter Net Income of $56.4M
L impact | EARNINGS | Nov 04, 2026, 02:00 PM UTC
G R Infraprojects Reports September-Quarter Revenue of 23.25 Billion Rupees
L impact | EARNINGS | Nov 04, 2026, 01:59 PM UTC
G R Infraprojects Reports September-Quarter Consolidated Net Profit of 2.93 Billion Rupees
M impact | EARNINGS | Nov 04, 2026, 01:58 PM UTC
Pandora Raises 2026 EBIT Margin Guidance to 22.5%-23%
Pandora raised its 2026 EBIT margin guidance to 22.5%-23%.
M impact | EARNINGS | Nov 04, 2026, 01:57 PM UTC